My research focuses on identifying the mechanisms leading to lung fibrosis (scarring). In the lung, IPF (idiopathic pulmonary fibrosis) is a disease characterized by progressive fibrosis of unclear etiology, resulting in the rapid development of respiratory failure and death. Myofibroblasts are the key effector cells in fibrotic diseases and are responsible for producing excessive extracellular matrix proteins. We have recently reported that the mechanistic target of rapamycin (mTOR) reconfigures the myofibroblast metabolic network to meet the biosynthetic demands associated with enhanced matrix biosynthesis. This new field coined ‘fibrometabolism’ has now emerged as an important research topic as it may offer a novel approach to target IPF and other fibrotic diseases.
View Ilan Azuelos’s recent posts and news:
Ilan Azuelos and Deborah Assayag are interviewed by the Montrealer for their Interstitial Lung Disease Clinic at the MUHC
Dr. Azuelos is dedicated to improving outcomes for ILD patients and their quality of life.
Congratulations to all Meakins and RECRU members who were funded in the Fall 2019 Project Grant Competition!
RI-MUHC, Block E
1001 Decarie Blvd.
Montreal QC H4A 3J1
Tel: 514-934-1934 Ext. 75260 (lab)
Tel: 514-934-1934 Ext. 76431 (office)
Tel: 514-934-1934 Ext. 76172 (admin)
E-Mail: ilan.azuelos [at] mcgill.ca
Education & Training
MD, McGill University, 2007